Literature DB >> 18234792

Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Tara L Tagmyer1, Jodi K Craigo, Sheila J Cook, Deborah L Even, Charles J Issel, Ronald C Montelaro.   

Abstract

A highly effective attenuated equine infectious anemia virus (EIAV) vaccine (EIAV(D9)) capable of protecting 100% of horses from disease induced by a homologous Env challenge strain (EIAV(PV)) was recently tested in ponies to determine the level of protection against divergent Env challenge strains (J. K. Craigo, B. S. Zhang, S. Barnes, T. L. Tagmyer, S. J. Cook, C. J. Issel, and R. C. Montelaro, Proc. Natl. Acad. Sci. USA 104:15105-15110, 2007). An inverse correlation between challenge strain Env variation and vaccine protection from disease was observed. Given the striking differences in protective immunity, we hypothesized that analysis of the humoral and cellular immune responses to the Env protein could reveal potential determinants of vaccine protection. Neutralization activity against the homologous Env or challenge strain-specific Env in immune sera from the vaccinated ponies did not correlate with protection from disease. Cellular analysis with Env peptide pools did not reveal an association with vaccine protection from disease. However, when individual vaccine-specific Env peptides were utilized, eight cytotoxic-T-lymphocyte (CTL) peptides were found to associate closely with vaccine protection. One of these peptides also yielded the only lymphoproliferative response associated with protective immunity. The identified peptides spanned both variable and conserved regions of gp90. Amino acid divergence within the principal neutralization domain and the identified peptides profoundly affected immune recognition, as illustrated by the inability to detect cross-reactive neutralizing antibodies and the observation that certain peptide-specific CTL responses were altered. In addition to identifying potential Env determinants of EIAV vaccine efficacy and demonstrating the profound effects of defined Env variation on immune recognition, these data also illustrate the sensitivity offered by individual peptides compared to peptide pools in measuring cellular immune responses in lentiviral vaccine trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234792      PMCID: PMC2292999          DOI: 10.1128/JVI.02028-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

2.  Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus.

Authors:  Darrilyn G Fraser; J Lindsay Oaks; Wendy C Brown; Travis C McGuire
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

3.  Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.

Authors:  Uma Malhotra; Fusheng Li; Jessica Nolin; Megan Allison; Hong Zhao; James I Mullins; Steve Self; M Juliana McElrath
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

4.  Response of ELA-A1 horses immunized with lipopeptide containing an equine infectious anemia virus ELA-A1-restricted CTL epitope to virus challenge.

Authors:  Sherritta L Ridgely; Baoshan Zhang; Travis C McGuire
Journal:  Vaccine       Date:  2003-01-17       Impact factor: 3.641

5.  Demonstration of three DRB loci in a domestic horse family.

Authors:  D G Fraser; E Bailey
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

6.  Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.

Authors:  Zane Kraft; Nina R Derby; Ruth A McCaffrey; Rachel Niec; Wendy M Blay; Nancy L Haigwood; Eirini Moysi; Cheryl J Saunders; Terri Wrin; Christos J Petropoulos; M Juliana McElrath; Leonidas Stamatatos
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

7.  Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.

Authors:  Laryssa Howe; Caroline Leroux; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus.

Authors:  Robert H Mealey; Baoshan Zhang; Steven R Leib; Matt H Littke; Travis C McGuire
Journal:  Virology       Date:  2003-09-01       Impact factor: 3.616

9.  A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.

Authors:  Feng Li; Jodi K Craigo; Laryssa Howe; Jonathan D Steckbeck; Sheila Cook; Charles Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization.

Authors:  Peng Fei Zhang; Fatim Cham; Ming Dong; Anil Choudhary; Peter Bouma; Zhiqiang Zhang; Yiming Shao; Yan-Ru Feng; Lemin Wang; Nathalie Mathy; Gerald Voss; Christopher C Broder; Gerald V Quinnan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-31       Impact factor: 11.205

View more
  17 in total

1.  Genomic analysis of an effective lentiviral vaccine-attenuated equine infectious anemia virus vaccine EIAV FDDV13.

Authors:  Xu Qi; Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Rongxian Shen; Fenglong Wang; Xiangang Kong; Zhiqiang Su; Jianhua Zhou
Journal:  Virus Genes       Date:  2010-06-05       Impact factor: 2.332

2.  Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus.

Authors:  Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Fenglong Wang; Rongxian Shen; Jianhua Zhou
Journal:  Virus Genes       Date:  2011-01-08       Impact factor: 2.332

3.  Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction.

Authors:  Egidio Brocca-Cofano; David Kuhrt; Basile Siewe; Cuiling Xu; George S Haret-Richter; Jodi Craigo; Celia Labranche; David C Montefiori; Alan Landay; Cristian Apetrei; Ivona Pandrea
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

4.  Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease.

Authors:  Jodi K Craigo; Shannon Barnes; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Vaccine       Date:  2010-10-16       Impact factor: 3.641

5.  Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.

Authors:  Chong Liu; Sheila J Cook; Jodi K Craigo; Frank R Cook; Charles J Issel; Ronald C Montelaro; David W Horohov
Journal:  Vet Immunol Immunopathol       Date:  2014-08-10       Impact factor: 2.046

6.  A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine.

Authors:  Qinglai Meng; Yuezhi Lin; Jian Ma; Yan Ma; Liping Zhao; Shenwei Li; Kai Yang; Jianhua Zhou; Rongxian Shen; Xiaoyan Zhang; Yiming Shao
Journal:  Viral Immunol       Date:  2012-11-21       Impact factor: 2.257

7.  The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies.

Authors:  Chong Liu; Frank R Cook; Sheila J Cook; Jodi K Craigo; Deborah L Even; Charles J Issel; Ronald C Montelaro; David W Horohov
Journal:  Vet Immunol Immunopathol       Date:  2012-06-23       Impact factor: 2.046

8.  Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.

Authors:  Lianxing Liu; Yanmin Wan; Lan Wu; Jianping Sun; Huiguang Li; Haishan Li; Liying Ma; Yiming Shao
Journal:  Retrovirology       Date:  2010-09-01       Impact factor: 4.602

9.  An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.

Authors:  Jodi K Craigo; Shannon Barnes; Baoshan Zhang; Sheila J Cook; Laryssa Howe; Charles J Issel; Ronald C Montelaro
Journal:  Retrovirology       Date:  2009-10-20       Impact factor: 4.602

10.  Envelope determinants of equine lentiviral vaccine protection.

Authors:  Jodi K Craigo; Corin Ezzelarab; Sheila J Cook; Liu Chong; David Horohov; Charles J Issel; Ronald C Montelaro
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.